Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview.

MLA

Wu, Changjin, et al. “Cost-Effectiveness of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels: A Comprehensive Overview.” Critical Reviews in Oncology/Hematology, vol. 193, Jan. 2024, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.critrevonc.2023.104195.

APA

Wu, C., Li, W., Tao, H., Zhang, X., Xin, Y., Song, R., Wang, K., Zuo, L., Cai, Y., Wu, H., & Hui, W. (2024). Cost-effectiveness of first-line immunotherapy for advanced non-small cell lung cancer with different PD-L1 expression levels: A comprehensive overview. Critical Reviews in Oncology/Hematology, 193, N.PAG. https://doi.org/10.1016/j.critrevonc.2023.104195

Chicago

Wu, Changjin, Wentan Li, Hongyu Tao, Xiyan Zhang, Yu Xin, Ruomeng Song, Kaige Wang, et al. 2024. “Cost-Effectiveness of First-Line Immunotherapy for Advanced Non-Small Cell Lung Cancer with Different PD-L1 Expression Levels: A Comprehensive Overview.” Critical Reviews in Oncology/Hematology 193 (January): N.PAG. doi:10.1016/j.critrevonc.2023.104195.